Image: Atomwise CEO and co-founder Abraham Heifets

Vaccines

GSK speeds up the race to market the first RSV vaccine for older adults

Recent data from GSK’s sub-unit vaccine, GSK-3844766A, have pushed the candidate to the top of the RSV vaccine race, say GlobalData analysts.

Dr Judith M. Sills. Credit: Arriello

Dr Eric Caugant. Credit: Arriello

After decades of setbacks, the respiratory syncytial virus (RSV) vaccine field has bounced back with positive Phase III trial results in older adults. There are currently five players in the race, with vaccines in Phase III of development from GlaxoSmithKline (GSK), Pfizer, Johnson & Johnson, Moderna and Bavarian Nordic. However, recent data from GSK’s sub-unit vaccine, GSK-3844766A, have pushed the candidate to the top, with the highest efficacy demonstrated in a pivotal trial to date. 

GSK’s Phase III pivotal trial included roughly 25,000 adults aged 60 years and older across 17 countries. The most recent results were announced on 13 October and showed an impressive 94.1% efficacy against severe RSV disease, along with an overall vaccine efficacy of 82.6%. The results also demonstrated consistent efficacy against both RSV subtypes, RSV-A and RSV-B, as well as a favourable safety profile. More specifically, the data suggest an efficacy rate of 93.8% in adults aged 70-79 years and 94.6% in adults with comorbidities such as cardiovascular conditions, which represent the patient populations at highest risk of death if contracting the virus. 

GSK’s RSV older adult vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein antigen combined with proprietary AS01E adjuvant. There are currently no approved RSV vaccines in any population. The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted GSK’s New Drug Application (NDA) for review in adults aged 60 years and older to prevent lower respiratory tract diseases caused by RSV. Further regulatory updates from the US and EU are expected by the end of the year. Those at high risk of severe illness from RSV include older adults, adults with chronic lung or heart disease, and adults with weakened immune systems. 

If approved, GSK’s GSK-3844766A will be the first vaccine to reach the market for the prevention of RSV in older adults, gaining a significant first-mover advantage. More importantly, this potential approval may dramatically reduce the global burden of RSV in older adults during the current Covid-19 pandemic.

Go to top

Go to top

11/23/2022 22:05:56
  • Home | What Rishi Sunak can do for the UK pharma industry
  • In this issue
  • Contents
  • CSafe
  • Tripletree
  • Briefing
  • Industry news
  • The pharma industry briefing
  • BEA Technologies
  • Mimotopes Company Insight
  • Mimotopes
  • Comment
  • GSK speeds up the race to market first RSV vaccine for older adults
  • Biden’s directive on foreign biotech investments impacts manufacturers
  • Novo Nordisk targets FDA approval for once-weekly insulin after Phase III data
  • ‘Twindemic’ risks warrant immediate steps in Europe and the US
  • A game of two halves for Roche’s recently approved wet AMD assets
  • Dr. Paul Lohmann
  • Nipro
  • In Depth
  • What Rishi Sunak can do for the UK pharma industry
  • Inside the European mass shift to data-driven health solutions
  • Chronic drug shortages signal difficult outlook for cardiovascular care
  • Can gene therapies for haemophilia defend their high price tags?
  • Trial termination analysis unveils a silver lining for patient recruitment
  • New dawn for the EU's joint procurement crisis response
  • Skyepharma
  • Bio Image Systems Inc.
  • In Data
  • The pharma industry found it easier to fill AI vacancies in Q3 2022
  • Internet of things hiring levels in the pharma dropped in October 2022
  • Artificial intelligence hiring levels in the pharma dropped in October 2022
  • Baxter
  • Events
  • Next issue